Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Celgene Cp Cvr (CELGZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.59 +8.37%
on 06/10/19
0.80 -20.08%
on 06/13/19
-0.02 (-3.12%)
since 05/24/19
3-Month
0.56 +14.18%
on 05/15/19
1.25 -48.85%
on 03/25/19
-0.61 (-48.84%)
since 03/22/19
52-Week
0.35 +82.69%
on 12/28/18
2.65 -75.87%
on 08/10/18
+0.25 (+63.95%)
since 06/22/18

Most Recent Stories

More News
Bristol-Myers Squibb Provides Update on Pending Merger with Celgene

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company's pending merger with Celgene Corporation (NASDAQ: CELG). The Company remains actively...

CELG : 93.47 (-5.50%)
CELGZ : 0.64 (unch)
BMY : 45.68 (-7.42%)
US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for ozanimod for the treatment of people...

CELG : 93.47 (-5.50%)
CELGZ : 0.64 (unch)
Bristol-Myers Squibb Announces Post-Closing Leadership Team

--Company well positioned for long-term growth, with strategic focus on Oncology, Hematology, Immunology, Cardiovascular, and Fibrosis

CELG : 93.47 (-5.50%)
CELGZ : 0.64 (unch)
BMY : 45.68 (-7.42%)
Celgene Updated Analysis of JAKARTA2 Fedratinib Study Shows Clinically Meaningful Responses in Patients Previously Treated for Myelofibrosis with Ruxolitinib

Celgene Corporation (NASDAQ: CELG) announced an updated analysis of data from the Phase 2 JAKARTA2 clinical study demonstrating clinically meaningful response rates with investigational fedratinib...

CELG : 93.47 (-5.50%)
CELGZ : 0.64 (unch)
FDA Approves REVLIMID(R) (Lenalidomide) In Combination With Rituximab For the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma

--Approval based on Phase 3 AUGMENT study, which showed the combination significantly improved median progression-free survival versus rituximab monotherapy

CELG : 93.47 (-5.50%)
CELGZ : 0.64 (unch)
Precision Therapeutics' Helomics Division Selected by AccuGenomics as Preferred Lab Partner for NIIMBL Grant

Precision Therapeutics Inc., (Nasdaq: AIPT) ("Precision" or "the Company"), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that its Helomics...

AIPT : 0.64 (+6.67%)
MRK : 85.51 (+1.11%)
BLFS : 16.36 (-1.21%)
CELGZ : 0.64 (unch)
Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors - Corrected Version

BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology...

CELG : 93.47 (-5.50%)
BSGM : 9.00 (-2.70%)
CELGZ : 0.64 (unch)
BMY : 45.68 (-7.42%)
Biotech Brief: Electrophysiology Devices Billion Dollar Market Growth Made Possible by Innovative Technologies

The Electrophysiology marketplace is: "set for explosive growth" says an industry publication. It stated: "In the world of cardiovascular devices, growth is generally created by sudden technological advancements...

CELG : 93.47 (-5.50%)
BSX : 42.01 (+0.77%)
JNJ : 143.06 (+0.68%)
BSGM : 9.00 (-2.70%)
CELGZ : 0.64 (unch)
BMY : 45.68 (-7.42%)
Celgene Receives European Commission Approvals for REVLIMID(R) (lenalidomide) and IMNOVID(R) (pomalidomide)-based Triplet Combination Regimens for Patients with Multiple Myeloma

--REVLIMID in combination with bortezomib and dexamethasone (RVd) in adult patients with previously untreated multiple myeloma who are not eligible for transplant

CELG : 93.47 (-5.50%)
CELGZ : 0.64 (unch)
Celgene to Highlight New and Updated Hematology and Oncology Clinical Data at Upcoming American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

Celgene Corporation (NASDAQ: CELG) today announced that data from more than 40 company-sponsored, global alliance and investigator-initiated clinical studies evaluating Celgene's investigational...

CELG : 93.47 (-5.50%)
CELGZ : 0.64 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft. Long term indicators fully support a continuation of the trend.

See More Share

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar